Second, treatment with decitabine, which induces demethylation of the PARK2 promoter and reexpression of endogenous PRKN in tumor cells (Figure 2, E and F), also induced HMGB1 release in the CM of multiple tumor types (Figure 3D). Here, HMGB1 is linked to neoplasm.